Phoenix PharmaLabs
About this raise
Phoenix PharmaLabs, with a post-money valuation of $26,790,283, iis Testing the Waters on NetCapital. The company is a preclinical drug discovery company dedicated to the development of potent, safe, non-addictive treatments for pain and addiction. John Lawson, PH.D. and Lawrence Toll, PH.D. founded Phoenix PharmaLabs. The crowdfunding round has a minimum raise of $10,000 and a maximum raise of $1,070,000. Phoenix PharmaLabs lead drug, PPL-103, has demonstrated in animal studies that it is a very potent painkiller (10x more potent than morphine), and is non-addictive, does not produce withdrawal, does not cause death from overdose at elevated doses, and causes no constipation.
Investment Overview
Invested $0 :
Deal Terms
Company & Team
Company
- Year Founded
- 2002
- Industry
- Healthcare & Pharmaceuticals
- Tech Sector
- Distribution Model
- B2B2C
- Margin
- High
- Capital Intensity
- High
Financials
- Revenue +1,828% YoY
- $1,285,068
- Monthly Burn
- $39,829
-
Runway
- 0 months
Upgrade to gain access
-
$12.50 /month
billed annually - Free portfolio tracking, data-driven ratings, AI analysis and reports
- Plan Includes:
- Everything in Free, plus
- Company specific
Kingscrowd ratings and analyst reports
- Deal explorer and side-by-side comparison
- Startup exit and failure tracking
- Startup market filters and historical industry data
- Advanced company search ( with ratings)
- Get Edge Annual
Edge
Company Funding & Growth
Funding history
Close Date | Platform | Valuation | Total Raised | Security Type | Status | Reg Type |
---|---|---|---|---|---|---|
06/18/2021 | Netcapital | $26,790,283 | $1,065,500 | Equity - Common | Funded | RegCF |
01/30/2021 | Netcapital | $26,790,283 | $0 | Equity - Common | Funded | Test the Waters |
03/30/2019 | Netcapital | $23,136,335 | $1,102,553 | Equity - Common | Funded | RegCF / RegD 506(c) |
Growth Charts
Revenue History
Note: Revenue data points reflect the latest of either the most recent fiscal year's financials, or updated revenues directly from the founder, at each raise's close date.
Valuation History
Price per Share History
Note: Share prices shown in earlier rounds may not be indicative of any stock splits.